Data gathered: April 21
Alternative Data for Gyre Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 50 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 200 | Sign up | Sign up | Sign up |
| Twitter Mentions | 17 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Gyre Therapeutics
None
| Price | $8.46 |
| Target Price | Sign up |
| Volume | 97,870 |
| Market Cap | $831M |
| Year Range | $6.41 - $16.8 |
| Dividend Yield | 0% |
| PE Ratio | 177.6 |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary ComplicationsMarch 30 - Yahoo |
|
We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) EarningsMarch 27 - Yahoo |
|
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational HepatologyMarch 26 - Yahoo |
 |
Gyre Therapeutics (GYRE) to Release Quarterly Earnings on TuesdayMarch 22 - ETF Daily News |
|
Gyre Therapeutics (NASDAQ:GYRE) Shares Gap Down After Earnings MissMarch 19 - ETF Daily News |
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 17 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 26M | 18M | 25M | 2.9M | 4.2M | 0.000 |
| Q2 '24 | 26M | 19M | 24M | 4.5M | 3.3M | 0.034 |
| Q1 '24 | 55M | 17M | 26M | 9.9M | 8.2M | 0.032 |
| Q4 '23 | 190M | 73M | 26M | -82M | -92M | |
| Q3 '23 | 32M | 2.4M | 31M | 7.5M | 13M | -1.050 |
Insider Transactions View All
| Ma Songjiang filed to sell 2,824,844 shares at $10. March 25 '25 |
| Ma Songjiang filed to sell 2,825,018 shares at $10.1. March 21 '25 |
| Ma Songjiang filed to sell 2,829,018 shares at $10.2. March 19 '25 |
| Ma Songjiang filed to sell 2,829,260 shares at $12.1. March 19 '25 |
| Ma Songjiang filed to sell 2,831,260 shares at $12.3. March 17 '25 |
Similar companies
Read more about Gyre Therapeutics (GYRE) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Gyre Therapeutics?
The Market Cap of Gyre Therapeutics is $831M.
What is Gyre Therapeutics' PE Ratio?
As of today, Gyre Therapeutics' PE (Price to Earnings) ratio is 177.6.
What is the current stock price of Gyre Therapeutics?
Currently, the price of one share of Gyre Therapeutics stock is $8.46.
How can I analyze the GYRE stock price chart for investment decisions?
The GYRE stock price chart above provides a comprehensive visual representation of Gyre Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Gyre Therapeutics shares. Our platform offers an up-to-date GYRE stock price chart, along with technical data analysis and alternative data insights.
Does GYRE offer dividends to its shareholders?
As of our latest update, Gyre Therapeutics (GYRE) does not offer dividends to its shareholders. Investors interested in Gyre Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Gyre Therapeutics?
Some of the similar stocks of Gyre Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.